ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers

Biliary tract cancer is a highly heterogeneous group of gastrointestinal cancers, and the only curative treatment is surgery, which is only applicable at early stages of the malignancy. ADJUBIL, a phase II trial (NCT05239169), aims to evaluate immunotherapy with durvalumab and tremelimumab with or w...

Full description

Saved in:
Bibliographic Details
Published inFuture oncology (London, England)
Main Authors Goetze, Thorsten, Gonzalez-Carmona, Maria A, Kochen, Lisa, Agaoglu, Nihat Bugra, Al-Batran, Salah-Eddin, Habibzada, Timorshah, Pons, Miriam, Brunner, Marius, Ettrich, Thomas J, Köhne, Claus-Henning, Roderburg, Christoph, Modest, Dominik
Format Journal Article
LanguageEnglish
Published England 01.02.2024
Subjects
biliary tract cancer
adjuvant therapy
durvalumab
tremelimumab
immunotherapy
QoL
Online AccessGet more information

Cover

More Information
Summary:Biliary tract cancer is a highly heterogeneous group of gastrointestinal cancers, and the only curative treatment is surgery, which is only applicable at early stages of the malignancy. ADJUBIL, a phase II trial (NCT05239169), aims to evaluate immunotherapy with durvalumab and tremelimumab with or without capecitabine in adjuvant situations for biliary tract cancers. A total of 40 prospective patients will be randomly assigned following surgery, consisting of a two-arm feasibility pilot part with a pick-the-winner design with durvalumab and tremelimumab in combination with or without capecitabine.
ISSN:1744-8301
DOI:10.2217/fon-2023-0961